Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma
Omkara Veeranki(The University of Texas MD Anderson Cancer Center), Dipen M. Maru(The University of Texas MD Anderson Cancer Center)
Cited by 13
Related Papers
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)
|Journal of Clinical Oncology|2020|391
Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes
|Clinical Cancer Research|2017|318
Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors
|Journal of Clinical Oncology|2023|193